RECRUITING

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Talk to us

Conditions

Relapsed or Refractory Hematologic MalignanciesHematologicMalignanciesCancerBlood

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

Official Title

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Quick Facts

Study Start:2018-09-27
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03838926

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Subject is ≥ 18 years at the time of signing informed consent;
  2. * Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;
  3. * Presence of measurable or evaluable disease;
  4. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;
  5. * Contraceptives or other approved avoidance of pregnancy measures
  1. * Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;
  2. * Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);
  3. * Undergone major surgery ≤ 2 weeks prior to starting study drug;
  4. * Evidence of mucosal or internal bleeding;
  5. * Impaired cardiac function or conduction defect;
  6. * Concurrent severe and/or uncontrolled medical conditions

Contacts and Locations

Study Contact

Vanda Pharmaceuticals
CONTACT
202-734-3400
clinicaltrials@vandapharma.com

Study Locations (Sites)

Vanda Investigational Site
Washington, District of Columbia, 20007
United States
Vanda Investigational Site
Lafayette, Indiana, 47905
United States
Vanda Investigational Site
Hackensack, New Jersey, 07601
United States
Vanda Investigational Site
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: Vanda Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-09-27
Study Completion Date2025-12

Study Record Updates

Study Start Date2018-09-27
Study Completion Date2025-12

Terms related to this study

Keywords Provided by Researchers

  • Hematologic
  • Malignancies
  • Cancer
  • Blood

Additional Relevant MeSH Terms

  • Relapsed or Refractory Hematologic Malignancies